Literature DB >> 4599607

Pulmonary deposition of aerosols in children with cystic fibrosis.

P O Alderson, R H Secker-Walker, D B Stominger, J Markham, R L Hill.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4599607     DOI: 10.1016/s0022-3476(74)80664-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  12 in total

1.  Pectus excavatum: studiously ignored in the United Kingdom?

Authors:  R Wheeler; K Foote
Journal:  Arch Dis Child       Date:  2000-03       Impact factor: 3.791

2.  How to choose delivery devices for asthma.

Authors:  C O'Callaghan; P W Barry
Journal:  Arch Dis Child       Date:  2000-03       Impact factor: 3.791

Review 3.  Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.

Authors:  N R Labiris; M B Dolovich
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 4.  Nebuliser therapy in childhood.

Authors:  P W Barry; C O'Callaghan
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

Review 5.  Aerosols for therapy and diagnosis.

Authors:  M J O'Doherty; R F Miller
Journal:  Eur J Nucl Med       Date:  1993-12

Review 6.  Studies using radiolabelled aerosols in children.

Authors:  M L Everard
Journal:  Thorax       Date:  1994-12       Impact factor: 9.139

7.  Crying significantly reduces absorption of aerosolised drug in infants.

Authors:  R Iles; P Lister; A T Edmunds
Journal:  Arch Dis Child       Date:  1999-08       Impact factor: 3.791

8.  Therapeutic aerosols in children.

Authors:  S H Thomas; S Batchelor; M J O'Doherty
Journal:  BMJ       Date:  1993-07-24

9.  Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers.

Authors:  S H Thomas; M J O'Doherty; A Graham; C J Page; P Blower; D M Geddes; T O Nunan
Journal:  Thorax       Date:  1991-10       Impact factor: 9.139

10.  Controlled trial of intermittent aerosol therapy with sodium 2-mercaptoethane sulphonate in cystic fibrosis.

Authors:  P H Weller; D Ingram; M A Preece; D J Matthew
Journal:  Thorax       Date:  1980-01       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.